Company Overview - InnoCare Pharma is a leading biopharmaceutical company focused on developing treatments for cancer and autoimmune diseases, with a commitment to addressing unmet medical needs globally [5] Product Approval - HIBRUKA (orelabrutinib) has received approval from the Health Sciences Authority (HSA) of Singapore for treating adult patients with relapsed or refractory marginal zone lymphoma (R/R MZL) [1][2] - This marks the second indication approval for orelabrutinib in Singapore, following its previous approval for other indications [2] Product Efficacy and Safety - Orelabrutinib is a highly selective BTK inhibitor that has shown good efficacy and safety in treating R/R MZL, providing a new treatment option for local lymphoma patients [2] - The drug's high target selectivity minimizes off-target effects, enhancing both safety and efficacy [2] Market Context - Marginal zone lymphoma (MZL) is an indolent B-cell non-Hodgkin's lymphoma primarily affecting middle-aged and elderly patients, with an increasing annual incidence globally [3] - Patients with R/R MZL often lack effective treatment options after first-line therapy [3] Previous Approvals - In April 2025, orelabrutinib was approved in China for the first-line treatment of chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) and has received approvals for three other indications, including R/R CLL/SLL, R/R mantle cell lymphoma (MCL), and R/R MZL, all included in China's National Reimbursement Drug List [4]

Core Viewpoint - InnoCare Pharma has initiated a registrational trial for mesutoclax, a BCL2 inhibitor, aimed at treating mantle cell lymphoma (MCL) patients previously treated with BTK inhibitors in China [1][3]. Group 1: Product and Mechanism - Mesutoclax is an orally bioavailable BCL2 selective inhibitor that targets the apoptosis pathway, which is crucial in the development of various hematologic malignancies [2]. - The drug has shown potential in treating multiple diseases, including MCL, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS) [2]. Group 2: Clinical Development - The registrational trial is specifically designed to assess the safety and efficacy of mesutoclax in patients with BTKi-treated MCL, which is characterized as an aggressive form of B-cell non-Hodgkin lymphoma with limited treatment options [3]. - InnoCare is advancing clinical trials for mesutoclax across four indications both in China and globally [2]. Group 3: Company Overview - InnoCare is a commercial stage biopharmaceutical company focused on discovering, developing, and commercializing innovative drugs for cancer and autoimmune diseases with unmet medical needs [4]. - The company has established branches in major cities including Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States [4].

Group 1 - The TERA-Award, hosted by Full Vision Capital, awarded the UK company Barocal with a gold medal and a prize of 1 million USD for its innovative solid-state cooling system [1][2] - Barocal's technology eliminates harmful refrigerants and enhances energy efficiency, providing sustainable solutions for the air conditioning and refrigeration sectors, with energy efficiency improvements of up to three times compared to traditional systems [2] - The event took place in Cambridge, UK, marking the first time the TERA-Award was held outside of Hong Kong, reflecting its growing international appeal and influence [1][2] Group 2 - The TERA-Award received support from various organizations, including the Hong Kong Investment Corporation and the UK Department for Business and Trade, highlighting a commitment to accelerating deep-tech energy innovation and commercializing zero-carbon solutions [3] - The event included an innovation showcase and forum focusing on global clean energy trends and the importance of collaboration in energy transition [2]

Core Insights - The TERA-Award, organized by Full Vision Capital, awarded the Gold Award to Barocal, a UK startup, for its innovative solid-state cooling system, which utilizes barocaloric materials and offers a sustainable alternative to traditional refrigerants [1][3][10] Group 1: Award Details - The Gold Award comes with a prize of US$1 million and recognizes Barocal's technology that enhances energy efficiency and eliminates harmful refrigerants [1][3] - The TERA-Award received 785 entries from 76 countries and regions, highlighting its international appeal [3][4] Group 2: Event Highlights - The award ceremony took place at King's College, University of Cambridge, attended by over 100 industry leaders, entrepreneurs, and investors [2] - An innovation showcase and forum were held to discuss global clean energy trends and the importance of collaboration in the energy transition [5] Group 3: Organizational Support - The fourth TERA-Award is supported by various organizations, including the Hong Kong Investment Corporation and the UK's Department for Business and Trade, indicating a commitment to advancing deep-tech energy innovation [6]

Core Insights - The TERA-Award has achieved record participation with 785 submissions from 76 countries, highlighting a global push for climate tech solutions [1][2][3] - The competition focuses on six categories, with Renewable Energy being the most prominent, showcasing innovations in green fuels, hydrogen technology, smart energy systems, and sustainable infrastructure [2][3] - The TERA-Award serves as a global platform for energy innovation, with significant contributions from the US (12.5%), UK (6.2%), India (8.7%), China (18.1%), and Hong Kong (5.5%) [3] Industry Impact - The TERA-Award not only offers a US$1 million grand prize but also has a history of transforming innovative ideas into commercial products, as seen with previous participants like i2Cool and Luquos Energy [4][5] - The competition is backed by industry leaders such as Towngas, providing participants with access to resources that can be more valuable than monetary awards [7] - The judging phase will be led by Professor Cui Yi, focusing on technological innovation, commercial viability, scalability, and potential global impact [6] Future Outlook - Winners will be announced in July 2025, with expectations that the competition will continue to discover promising energy startups to combat the climate crisis [11]